19-11039552-A-G
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_001387283.1(SMARCA4):c.4265A>G(p.Lys1422Arg) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. 11/16 in silico tools predict a benign outcome for this variant. 2/3 splice prediction tools predict no significant impact on normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. K1422E) has been classified as Uncertain significance.
Frequency
Consequence
NM_001387283.1 missense, splice_region
Scores
Clinical Significance
Conservation
Publications
- Coffin-Siris syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: ClinGen, Orphanet, Illumina
- intellectual disability, autosomal dominant 16Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), Ambry Genetics
- rhabdoid tumor predisposition syndrome 2Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, ClinGen, Genomics England PanelApp, Labcorp Genetics (formerly Invitae), G2P
- uterine corpus sarcomaInheritance: AR Classification: MODERATE Submitted by: Genomics England PanelApp
- familial rhabdoid tumorInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Likely_benign. The variant received -2 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SMARCA4 | NM_001387283.1 | c.4265A>G | p.Lys1422Arg | missense_variant, splice_region_variant | Exon 30 of 36 | ENST00000646693.2 | NP_001374212.1 | |
| SMARCA4 | NM_003072.5 | c.4171-1755A>G | intron_variant | Intron 29 of 34 | ENST00000344626.10 | NP_003063.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SMARCA4 | ENST00000646693.2 | c.4265A>G | p.Lys1422Arg | missense_variant, splice_region_variant | Exon 30 of 36 | NM_001387283.1 | ENSP00000495368.1 | |||
| SMARCA4 | ENST00000643549.1 | c.4166A>G | p.Lys1389Arg | missense_variant, splice_region_variant | Exon 29 of 35 | ENSP00000493975.1 | ||||
| SMARCA4 | ENST00000344626.10 | c.4171-1755A>G | intron_variant | Intron 29 of 34 | 1 | NM_003072.5 | ENSP00000343896.4 | |||
| SMARCA4 | ENST00000541122.6 | c.4072-1746A>G | intron_variant | Intron 29 of 34 | 5 | ENSP00000445036.2 | ||||
| SMARCA4 | ENST00000643296.1 | c.4072-1746A>G | intron_variant | Intron 28 of 33 | ENSP00000496635.1 | |||||
| SMARCA4 | ENST00000644737.1 | c.4072-1746A>G | intron_variant | Intron 28 of 33 | ENSP00000495548.1 | |||||
| SMARCA4 | ENST00000589677.5 | c.4072-1746A>G | intron_variant | Intron 29 of 34 | 5 | ENSP00000464778.1 | ||||
| SMARCA4 | ENST00000643995.1 | c.3583-1746A>G | intron_variant | Intron 26 of 31 | ENSP00000496004.1 | |||||
| SMARCA4 | ENST00000644963.1 | c.2815-1746A>G | intron_variant | Intron 22 of 27 | ENSP00000495599.1 | |||||
| SMARCA4 | ENST00000644065.1 | c.2797-1746A>G | intron_variant | Intron 21 of 26 | ENSP00000493615.1 | |||||
| SMARCA4 | ENST00000642350.1 | c.2656-1746A>G | intron_variant | Intron 21 of 26 | ENSP00000495355.1 | |||||
| SMARCA4 | ENST00000643857.1 | c.2524-1746A>G | intron_variant | Intron 20 of 24 | ENSP00000494159.1 | |||||
| SMARCA4 | ENST00000538456.4 | c.328-1746A>G | intron_variant | Intron 3 of 7 | 3 | ENSP00000495197.1 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 27
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Rhabdoid tumor predisposition syndrome 2 Uncertain:1
This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 1422 of the SMARCA4 protein (p.Lys1422Arg). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SMARCA4-related conditions. ClinVar contains an entry for this variant (Variation ID: 470386). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
Hereditary cancer-predisposing syndrome Uncertain:1
The p.K1422R variant (also known as c.4265A>G), located in coding exon 29 of the SMARCA4 gene, results from an A to G substitution at nucleotide position 4265. The lysine at codon 1422 is replaced by arginine, an amino acid with highly similar properties. This amino acid position is conserved on limited sequence alignment. In addition, this alteration is predicted to be tolerated by in silico analysis. Missense and in-frame variants in SMARCA4 are known to cause neurodevelopmental disorders; however, such associations with rhabdoid tumor predisposition syndrome including small cell carcinoma of the ovary-hypercalcemic type (SCCOHT) are exceedingly rare (Kosho T et al. Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):262-75; Jelinic P et al. Nat Genet. 2014 May;46(5):424-6). Based on the supporting evidence, the association of this alteration with Coffin-Siris syndrome is unknown; however, the association of this alteration with rhabdoid tumor predisposition syndrome is unlikely. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at